The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis: A Cohort Study
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether obesity is associated with a better prognosis in patients with type 2 diabetes mellitus is controversial. OBJECTIVE: To investigate the association between body weight and prognosis in a large cohort of patients with type 2 diabetes followed for a prolonged period. DESIGN: Prospective cohort. SETTING: National Health Service, England. PATIENTS: Patients with diabetes. MEASUREMENTS: The relationship between body mass index (BMI) and prognosis in patients with type 2 diabetes without known cardiovascular disease at baseline was investigated. Information on all-cause mortality and cardiovascular morbidity (such as the acute coronary syndrome, cerebrovascular accidents, and heart failure) was collected. Cox regression survival analysis, corrected for potential modifiers, including cardiovascular risk factors and comorbid conditions (such as cancer, chronic kidney disease, and lung disease), was done. RESULTS: 10,568 patients were followed for a median of 10.6 years (interquartile range, 7.8 to 13.4). Median age was 63 years (interquartile range, 55 to 71), and 54% of patients were men. Overweight or obese patients (BMI >25 kg/m²) had a higher rate of cardiac events (such as the acute coronary syndrome and heart failure) than those of normal weight (BMI, 18.5 to 24.9 kg/m²). However, being overweight (BMI, 25 to 29.9 kg/m²) was associated with a lower mortality risk, whereas obese patients (BMI >30 kg/m²) had a mortality risk similar to that of normal-weight persons. Patients with low body weight had the worst prognosis. LIMITATION: Data about cause of death were not available. CONCLUSION: In this cohort, patients with type 2 diabetes who were overweight or obese were more likely to be hospitalized for cardiovascular reasons. Being overweight was associated with a lower mortality risk, but being obese was not. PRIMARY FUNDING SOURCE: National Institute for Health Research and University of Hull.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although obesity is a major risk factor for T2D, paradoxically overweight and obese patients have been reported to have had a lower mortality rate than normal-weight patients due to cardiovascular pathology associated with T2D and this phenomenon was termed “the obesity paradox”.134,135”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [134]
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Our study suggests that type 2 diabetes induced by the metabolic stress of obesity may fundamentally differ from that which develops in the absence of obesity (32, 33).”
BackgroundRandomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563 · cited 1×
“long-term follow-up; include relevant confounding factors, such as comorbid conditions; not include patients who are underweight in the normal-weight group; use primary data (collected by the investigator for the purpose of the study); and use consistent data definitions, which might be best achieved in a single cente…”
MethodCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · cited 1×
“However, the intervention had little effect on weight (36, 37).”
BackgroundBody-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old
Adams, K. F., Schatzkin, A., Harris, T. B., Kipnis, V., Mouw, T., Ballard-Barbash, R., Hollenbeck, A., & Leitzmann, M. F. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055643 · Cited by 2,116 · cited 1×
“The association between obesity and increased risk for cardiovascular disease (CVD) is well-established in the general population (5, 6).”
BackgroundWaist circumference and not body mass index explains obesity-related health risk
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.379 · Cited by 2,013 · cited 1×
“However, BMI is still conventionally accepted as a measure of obesity (50).”
BackgroundWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · cited 1×
“Obese patients with type 2 diabetes might not have diabetes if they lost weight (34).”
BackgroundFitting curves to data using nonlinear regression: a practical and nonmathematical review
Motulsky, H. J., & Ransnas, L. A. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.5.3315805 · Cited by 1,327 · cited 1×
“The interaction between age (as a continuous variable) and BMI categories was also investigated using a logistic regression analysis (26, 27).”
MethodActive Smoking and the Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis
Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007) · JAMA · doi:10.1001/jama.298.22.2654 · Cited by 1,268
Pathophysiology of insulin resistance in human disease
Reaven, G. M. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.473 · Cited by 1,226 · cited 1×
“Obesity, which promotes insulin resistance, may account for 80% of the population-attributable risk for type 2 diabetes (2).”
Background
Research works printed but not linked: 1
- 1995, World Health Organ Tech Rep Ser, 854, 1
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study
Puzianowska-Kuźnicka, M., Owczarz, M., Wieczorowska-Tobis, K., Nadrowski, P., Chudek, J., Slusarczyk, P., Skalska, A., Jonas, M., Franek, E., & Mossakowska, M. (2016) · Immunity & Ageing · doi:10.1186/s12979-016-0076-x · Cited by 445
“Such a U-shaped relationship between BMI and proinflammatory factors supports the theory of the “obesity paradox” stating that in the elderly, lower morbidity and mortality are associated with a normal body weight or being overweight [43–46], whereas being underweight or obese (especially morbidly obese) poses a high…”
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Why primary obesity is a disease?
De Lorenzo, A., Gratteri, S., Gualtieri, P., Cammarano, A., Bertucci, P., & Di Renzo, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1919-y · Cited by 370
Muscle mass, BMI, and mortality among adults in the United States: A population-based cohort study
Abramowitz, M. K., Hall, C. B., Amodu, A., Sharma, D., Androga, L., & Hawkins, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194697 · Cited by 223
Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study
Padwal, R., Leslie, W. D., Lix, L. M., & Majumdar, S. R. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1181 · Cited by 235
Antonopoulos, A. S., Oikonomou, E. K., Antoniades, C., & Tousoulis, D. (2016) · Obesity Reviews · doi:10.1111/obr.12440 · Cited by 232
“(19) first described the paradoxical survival advantage of patients with higher than normal weight versus normal weight patients following percutaneous coronary intervention (PCI), numerous studies have reported similar findings in CHD (20), postrevascularization procedures (PCI (21) or coronary artery bypass grafting…”
BackgroundResultInfluentialIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
“568 type 2 diabetes patients show that being overweight compared to normal weight was associated with higher rates of cardiac events but with lower mortality which was suggested to be due to protection against osteoporosis and thereby fractures which increase mortality (54).”
BackgroundQiao, T., Luo, T., Pei, H., Yimingniyazi, B., Aili, D., Aimudula, A., Zhao, H., Zhang, H., Dai, J., & Wang, D. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01670-x · Cited by 175
Body composition phenotypes and obesity paradox
Prado, C. M., Gonzalez, M. C., & Heymsfield, S. B. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000216 · Cited by 155
Al-Mhanna, S. B., Batrakoulis, A., Ghazali, W. S. W., Mohamed, M., Aldayel, A. A., Alhussain, M. H., Afolabi, H. A., Wada, Y., Gülü, M., Elkholi, S. M. A., et al. (2024) · PeerJ · doi:10.7717/peerj.17525 · Cited by 178
“Populations with T2DM and concurrent are at high risk of experiencing raised blood pressure, resulting in a high risk of cardiovascular disease morbidity and mortality ( Costanzo et al., 2015 ).”
BackgroundZaccardi, F., Dhalwani, N. N., Papamargaritis, D., Webb, D. R., Murphy, G. J., Davies, M. J., & Khunti, K. (2017) · Diabetologia · doi:10.1007/s00125-016-4162-6 · Cited by 140
“5 kg/m(2)), and a similar mortality risk in obese (BMI ≥30 kg/m(2)) people compared with those with normal weight, indicating a nonlinear association between BMI and all-cause mortality [12].”
BackgroundFan, H., Li, X., Zheng, L., Chen, X., Lan, Q., Wu, H., Ding, X., Qian, D., Shen, Y., Yu, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep21521 · Cited by 151
The Evidence for an Obesity Paradox in Type 2 Diabetes Mellitus
Han, S. J., & Boyko, E. J. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0055 · Cited by 123
“[22] also showed that the optimal BMI for survival in a British cohort of patients with type 2 diabetes mellitus followed for a median of 10.”
BackgroundExploring the Impact of Obesity on Skeletal Muscle Function in Older Age
Morgan, P. T., Smeuninx, B., & Breen, L. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.569904 · Cited by 98
Kwon, Y., Kim, H. J., Park, S. S., Park, Y. G., & Cho, K.-H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168247 · Cited by 108
“Only eight studies chose categories corresponding to the World Health Organization recommendation [3,16,18,19,21,22,24,26].”
BackgroundZhang, J., Begley, A., Jackson, R., Harrison, M., Pellicori, P., Clark, A. L., & Cleland, J. G. F. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1302-7 · Cited by 113
“This is true for hypertension [47], type-2 diabetes mellitus [48, 49], atrial fibrillation [50, 51] and ischaemic heart disease [52] as well as heart failure [53–55].”
BackgroundSelf-citationBrown, O. I., Drozd, M., McGowan, H., Giannoudi, M., Conning-Rowland, M. S., Gierula, J., Straw, S., Wheatcroft, S. B., Bridge, K., Roberts, L. D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0294 · Cited by 115
“In a prospective cohort of 10,568 people with type 2 diabetes, Costanzo and colleagues (24,25) showed that overweight and obese people were more likely to be hospitalized for MI or stroke, although cardiovascular mortality was not reported.”
BackgroundShi, T., Wang, B., & Natarajan, S. (2020) · Preventing Chronic Disease · doi:10.5888/pcd17.200020 · Cited by 104
Roumie, C. L., Min, J. Y., D'Agostino McGowan, L., Presley, C., Grijalva, C. G., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Elasy, T., & Griffin, M. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005379 · Cited by 95
“Another recent observational cohort followed more than 10 000 patients in a United Kingdom diabetes registry for more than 10 years.(42) The risk of incident heart failure was 2 times higher among obese patients (BMI ≥30 kg/m(2)) in all age tertiles compared with patients whose BMI was between 18.”
Doehner, W., Gerstein, H. C., Ried, J., Jung, H., Asbrand, C., Hess, S., & Anker, S. D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa293 · Cited by 92
“Previous registry data suggest a survival benefit in overweight patients with DM without CV disease compared to normal weight.(10) While most clinical data on body weight and outcome report on a single-time assessment of body weight, prospective evidence on weight change affecting outcome is limited and not supportive…”
BackgroundPolemiti, E., Baudry, J., Kuxhaus, O., Jäger, S., Bergmann, M. M., Weikert, C., & Schulze, M. B. (2021) · Diabetologia · doi:10.1007/s00125-020-05362-7 · Cited by 101
Zhao, X., He, Q., Zeng, Y., & Cheng, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046252 · Cited by 81
Al-Mhanna, S. B., Rocha‐Rodrigues, S., Mohamed, M., Batrakoulis, A., Aldhahi, M. I., Afolabi, H. A., Yağın, F. H., Alhussain, M. H., Gülü, M., Abubakar, B. D., et al. (2023) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-023-00766-5 · Cited by 95
“Individuals with T2DM and obesity tend to present with elevated blood pressure levels, resulting in an increased risk of developing cardiovascular disease morbidity and mortality [56].”
BackgroundAl-Mhanna, S. B., Franklin, B. A., Jakicic, J. M., Stamatakis, E., Pescatello, L. S., Riebe, D. A., Thompson, W. R., Skinner, J. S., Colberg, S. R., Alkhamees, N. H., et al. (2025) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108947 · Cited by 87
“84 According to the latest international recommendations, it is critically important for this population to have a normal blood lipid profile to lower the risk of developing metabolic syndrome.”
Chen, M., Zhao, C.-C., Li, T., Zhu, Y., Yu, T.-P., Bao, Y., Li, L., & Jia, W. (2017) · Scientific Reports · doi:10.1038/srep40009 · Cited by 78
Pathophysiology‐based phenotyping in type 2 diabetes: A clinical classification tool
Stidsen, J. V., Henriksen, J. E., Olsen, M. H., Thomsen, R. W., Nielsen, J. S., Rungby, J., Ulrichsen, S. P., Berencsi, K., Kahlert, J. A., Friborg, S. G., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3005 · Cited by 72
“CVD(43) and is possible a main mediator of the higher cardiovascular occurrence in hyperinsulinemic patients, although the association with obesity is complex in patients with type 2 diabetes.(44,45) As the cause‐ and‐effect directions in the pathophysiological pathways of obesity and IR are impossible to disentangle…”
BackgroundPagidipati, N. J., Zheng, Y., Green, J. B., McGuire, D. K., Mentz, R. J., Shah, S., Aschner, P., Delibasi, T., Rodbard, H. W., Westerhout, C. M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2019.09.016 · Cited by 74
Lee, E. Y., Lee, Y., Yi, S., Shin, S., & Yi, J. (2017) · Diabetes Care · doi:10.2337/dc16-1458 · Cited by 67
Scientific Weightism: A View of Mainstream Weight Stigma Research Through a Feminist Lens
Calogero, R. M., Tylka, T. L., & Mensinger, J. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-32141-7_2 · Cited by 63
Adipokines and Migraine: A Systematic Review
Peterlin, B. L., Sacco, S., Bernecker, C., & Scher, I. (2016) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12788 · Cited by 60
The obesity paradox and diabetes
Gravina, G., Ferrari, F., & Nebbiai, G. (2020) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-01015-1 · Cited by 56
Zareini, B., Rørth, R., Holt, A., Mogensen, U. M., Selmer, C., Gislason, G., Schou, M., Køber, L., Torp-Pedersen, C., Lamberts, M., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0883-4 · Cited by 49
Kammerlander, A. A., Mayrhofer, T., Ferencik, M., Pagidipati, N. J., Karády, J., Ginsburg, G. S., Lu, M. T., Bittner, D. O., Puchner, S. B., Bihlmeyer, N. A., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1760 · Cited by 50
“Notably, other factors have been discussed as potential confounders, including a more aggressive therapy regimen in patients with obesity (36) and a lead-time bias, describing the phenomenon that CVD occurs at younger age in obese individuals when they have fewer comorbidities compared with nonobese subjects (37).”
BackgroundRelative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity
Ziolkowski, S., Long, J., Baker, J. F., Chertow, G. M., & Leonard, M. B. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12396 · Cited by 43
Tate, J., Knuiman, M. W., Davis, W. A., Davis, T. M. E., & Bruce, D. G. (2019) · Diabetologia · doi:10.1007/s00125-019-05057-8 · Cited by 45
Berk, K. A., Yahya, R., Verhoeven, A. J. M., Touw, J., Leijten, F. P. J., van Rossum, E. F. C., Wester, V. L., Lips, M. A., Pijl, H., Timman, R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4246-y · Cited by 43
Xiao, N., Ding, Y., Cui, B., Li, R., Qu, X.-R., Zhou, H., Au, K.-H., Fan, X.-D., Xie, J.-C., Huang, Y., et al. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100090 · Cited by 43
Wang, P., Fan, Y., Gao, H., & Wang, B. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111958 · Cited by 41
Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries
Hartmann, B., Lanzinger, S., Bramlage, P., Groß, F., Danne, T., Wagner, S., Krakow, D., Zimmermann, A., Malcharzik, C., & Holl, R. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183235 · Cited by 40
Nuertey, B. D., Alhassan, A. I., Nuertey, A. D., Mensah, I. A., Adongo, V., Kabutey, C., Addai, J. A., & Biritwum, R. B. (2017) · BMC Obesity · doi:10.1186/s40608-017-0162-4 · Cited by 42
Orsi, E., Solini, A., Penno, G., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Lamacchia, O., Haxhi, J., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01706-2 · Cited by 41
Chang, H., Li, Y.-H., Hsieh, C., Liu, P., & Lin, G. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.12.06 · Cited by 36
“In summary, the U-shaped relationship was reported in eleven studies (6-8,10,16,19,21-24,26).”
BackgroundMethodInfluentialMcAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Cohort Profile: The Rural Chinese Cohort Study
Zhang, M., Zhao, Y., Sun, L., Xi, Y., Zhang, W., Lu, J., Hu, F., Shi, X., & Hu, D. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa204 · Cited by 37
Al-Mhanna, S. B., Alghannam, A. F., Alkhamees, N. H., Sheeha, B. H. B., Omar, N., Albalawi, H., Gülü, M., Canlı, U., Afolabi, H. A., Abubakar, B. D., et al. (2025) · PeerJ · doi:10.7717/peerj.19537 · Cited by 38
“Individuals with T2DM and concurrent overweight/obesity are likely to experience poor lipid pro fi le, promoting cardiovascular complications ( Costanzo et al., 2015 ; Tan et al., 2023 ).”
A Glimpse into Milestones of Insulin Resistance and an Updated Review of Its Management
Aedh, A. I., Alshahrani, M. S., Huneif, M. A., Pryme, I. F., & Oruch, R. (2023) · Nutrients · doi:10.3390/nu15040921 · Cited by 38
“The aim is to treat the obesity in these individuals if they should be so affected [82].”
BackgroundBadrick, E., Sperrin, M., Buchan, I. E., & Renehan, A. G. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000369 · Cited by 33
“2015 UK[9] Outpatient clinic service for diabetes in Kingston upon Hull (UK), which serves a population of approximately 600 000 persons, were enrolled in a registry between 1995 and 2005 10,568 63 yr 16% all-cause mortality 3728 (35.”
BackgroundPatorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 31
“Using three propensity-score-matched cohorts that included >70 000 unique patients with T2DM from a large commercial US health insurance database, we found no significant difference in occurrence of CVD endpoints associated with initiation of GLP-1 RAs compared with initiation of DPP-4 inhibitors, second-generation su…”
BackgroundInfluentialTaieb, A. B., Roberts, E., Luckevich, M., Larsen, S., le Roux, C. W., de Freitas, P. G., & Wolfert, D. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00952-4 · Cited by 33
“Only 17% of the risk equations detailed the BMI of the cohort used to develop and/or validate the risk equation by obesity class beyond ≥ 30 kg/m2 [30, 42, 49, 52, 56].”
BackgroundMethodInfluentialLiu, H., Wu, S., Li, Y., Sun, L., Huang, Z., Lin, L., Liu, Y., Ji, C., Zhao, H., Li, C., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.015 · Cited by 31
Association between body mass index and mortality in a prospective cohort of Chinese adults
Sun, H., Ren, X., Chen, Z., Li, C., Chen, S., Wu, S., Chen, Y., & Yang, X. (2016) · Medicine · doi:10.1097/md.0000000000004327 · Cited by 34
“Keywords: all-cause mortality, body mass index, Chinese, obesity, obesity paradox [3]”
Spaetgens, B., Brouns, S. H. A., Linkens, A. E. M. J. H., Poeze, M., ten Broeke, R. H. M., Brüggemann, R. A. G., Sipers, W. M. W. H., Henry, R. M. A., & Hanssen, N. M. J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110084 · Cited by 29
Chen, Y., Yang, X., Wang, J., Li, Y., Ying, D., & Yuan, H. (2018) · Medicine · doi:10.1097/md.0000000000012075 · Cited by 28
Effect of Body Mass Index on the Prognosis of Liver Cirrhosis
Yin, Y., Li, Y., Shao, L., Yuan, S., Liu, B., Lin, S., Yang, Y., Tang, S., Meng, F., Wu, Y., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.700132 · Cited by 29
Khalil, C. A., Sulaiman, K., Singh, R., Jayyousi, A., Asaad, N., AlHabib, K. F., Alsheikh-Ali, A. A. A., Al‐Jarallah, M., Bulbanat, B., Almahmeed, W. A., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.119 · Cited by 29
Lin, C., Li, C.-I., Liu, C.-S., Lin, C., Lin, C., Chiang, J., Yang, S.-Y., & Li, T. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.02.007 · Cited by 29
Association of BMI, comorbidities and all-cause mortality by using a baseline mortality risk model
Li, J., Simon, G., Castro, M. R., Kumar, V., Steinbach, M. S., & Caraballo, P. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253696 · Cited by 27
“Many possible methodological biases have been proposed, including reverse causation, confounding factors, and several biases such as selection, survival and treatment biases [22, 35].”
BackgroundBoye, K. S., Ford, J. H., Thieu, V. T., Lage, M. J., & Terrell, K. A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01384-7 · Cited by 26
“ASCVD and Atrial Fibrillation Prior research has found that having overweight or obese is associated with a higher risk of cardiovascular events among individuals with T2D [31].”
BackgroundLi, W., Shi, D., Song, W., Xu, L., Zhang, L., Feng, X., Lu, R., Wang, X., & Meng, H. (2018) · Journal of Periodontology · doi:10.1002/jper.18-0064 · Cited by 26
Okuno, T., Koseki, K., Nakanishi, T., Ninomiya, K., Tomii, D., Tanaka, T., Sato, Y., Osanai, A., Sato, K., Koike, H., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0709 · Cited by 29
Renal Function in Type 2 Diabetes Following Gastric Bypass
Billeter, A. T., Kopf, S., Zeier, M. G., Scheurlen, K. M., Fischer, L., Schulte, T., Kenngott, H., Israel, B., Knefeli, P., Büchler, M. W., et al. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0827 · Cited by 29
Alexopoulos, A., Fayfman, M., Zhao, L., Weaver, J., Buehler, L. A., Smiley, D. D., Pasquel, F. J., Vellanki, P., HAW, J. S., & Umpierrez, G. E. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000200 · Cited by 26
Al-Mhanna, S. B., Franklin, B. A., Jakicic, J. M., Stamatakis, E., Pescatello, L. S., Riebe, D. A., Thompson, W. R., Skinner, J. S., Colberg, S. R., Ehrman, J. K., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109203 · Cited by 26
The Usefulness of Selected Biomarkers in Patients With Valve Disease
Duchnowski, P., Hryniewiecki, T., Kuśmierczyk, M., & Szymański, P. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0101 · Cited by 24
Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?
Ziolkowski, S., Long, J., Baker, J. F., Chertow, G. M., & Leonard, M. B. (2019) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2018.11.011 · Cited by 23
Body Mass Index and Prognosis in Ischemic Stroke Patients With Type 2 Diabetes Mellitus
Park, H., Lee, H. W., Yoo, J., Lee, H. S., Nam, H. S., Kim, Y. D., & Heo, J. H. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00563 · Cited by 24
Huber, M. B., Kurz, C., Kirsch, F. W., Schwarzkopf, L., Schramm, A., & Leidl, R. (2020) · Respiratory Research · doi:10.1186/s12931-020-01556-0 · Cited by 25
Tian, S., Liu, Y., Feng, A., & Zhang, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573452 · Cited by 20
The Obesity Paradox in Type 2 Diabetes and Mortality
Tobias, D. K., & Manson, J. E. (2016) · American Journal of Lifestyle Medicine · doi:10.1177/1559827616650415 · Cited by 21
Palazzuoli, A., Ruocco, G. M., & Gronda, E. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09972-6 · Cited by 22
Li, D., Jia, Y., Yu, J., Liu, Y., Li, F., Liu, Y., Wu, Q., Liao, X., Zeng, Z., Wan, Z., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.698608 · Cited by 23
Personalized Therapy by Phenotype and Genotype
Lyssenko, V., Bianchi, C., & Prato, S. D. (2016) · Diabetes Care · doi:10.2337/dcs15-3002 · Cited by 19
“SGLT2 inhibitors have the potential of reducing CV risk given their glucoselowering efficacy associated with sustained moderate weight loss and blood pressure reduction and lowering of uric acid levels (11).”
BackgroundNa, K., Kim, J., Paik, J., Cho, W., Ha, M., Park, Y. G., & Yang, S.-W. (2020) · Medicine · doi:10.1097/md.0000000000019285 · Cited by 20
Brady, C. F. (2016) · Social Sciences · doi:10.3390/socsci5010012 · Cited by 19
“Other studies demonstrate that among those that are physically active or fit, there is not an increased health risk associated with obesity [7,8], and that overweight and obese patients may be more likely to survive heart incidents or heart procedures [9,10].”
Billeter, A. T., Herrera, J. R. D. L. G., Scheurlen, K. M., Nickel, F., Billmann, F. G., & Müller-Stich, B. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0009 · Cited by 20
Franssens, B. T., Westerink, J., van der Graaf, Y., Nathoe, H. M., & Visseren, F. L. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.081 · Cited by 20
Kaneko, M., Fujihara, K., Yamada, M. H., OSAWA, T., Yamamoto, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., Seida, H., Kodama, S., et al. (2021) · Journal of Foot and Ankle Research · doi:10.1186/s13047-021-00474-8 · Cited by 18
“Another possibility is that our findings reflected an obesity paradox in patients with diabetes [34].”
BackgroundAdjah, E. S. O., Samanta, M., Shaw, J. E., Majeed, A., Khunti, K., & Paul, S. K. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-018-0042-0 · Cited by 30
“While some studies reported signi fi cantly higher mortality risk in those with normal body weight at diagnosis of T2DM, compared to those with obesity 1 – 8 , others could not fi nd such evidence 9,10 .”
ResultMekhaimar, M., Dargham, S. R., Elshazly, M. B., Suwaidi, J. M. S. A., Jneid, H. M., & Khalil, C. A. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10012-6 · Cited by 18
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16
Kocarnik, B. M., Moore, K. P., Smith, N. L., & Boyko, E. J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.025 · Cited by 16
Wang, Z., Dong, B., Hu, J., Adegbija, O., & Arnold, L. W. (2016) · Diabetic Medicine · doi:10.1111/dme.13111 · Cited by 17
Tsujimoto, T., Kajio, H., & Sugiyama, T. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.08.018 · Cited by 16
Li, D., Jia, Y., Yu, J., Liu, Y., Li, F., Liu, Y., Wu, Q., Liao, X., Zeng, Z., Zeng, R., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.698699 · Cited by 15
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.009 · Cited by 17
Janota, O., Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Lam, S. H. M., Huang, B., Alam, U., Boriani, G., Hendel, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02420-x · Cited by 15
“This relative contribution of obesity requires further elucidation over the presence of other CV risk factors in determining the risk of adverse events in people with DM [13–16].”
BackgroundResultMasoudkabir, F., Yavari, N., Jameie, M., Pashang, M., Sadeghian, S., Salarifar, M., Jalali, A., Tafti, S. H. A., Abbasi, K., Omran, A. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274129 · Cited by 14
Wang, Z., Lavikainen, P., Wikström, K., & Laatikainen, T. K. (2024) · Clinical Epidemiology · doi:10.2147/clep.s450455 · Cited by 14
Jung, M., Yi, S., An, S. J., Balkau, B., Yi, J., & Kim, H. (2020) · Diabetologia · doi:10.1007/s00125-020-05160-1 · Cited by 14
Body mass index and the risk of mortality among Chinese adults with Type 2 diabetes
Xu, H., Zhang, M., Xu, D., Zhang, F., Yao, B., Yan, Y., Zhao, N., Xu, W., & Qin, G. (2018) · Diabetic Medicine · doi:10.1111/dme.13763 · Cited by 14
Zhao, Y., Liu, Y., Sun, H., Sun, X., Yin, Z., Li, H., Ren, Y., Wang, B., Zhang, D., Liu, X., et al. (2018) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2017-210277 · Cited by 13
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus
Thakker, J., Khaliq, I., Ardeshna, N. S., Lavie, C. J., & Oktay, A. A. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01592-4 · Cited by 14
“Despite the potential improved outcomes observed in some obese individuals with T2D, the overall risk of complications such as CVD, kidney disease, and neuropathy remains significantly elevated in this population [ 17].”
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.06.005 · Cited by 13
Yoshihisa, A., Sato, T., Kajimoto, K., Sato, N., Takeishi, Y., & on behalf of the Acute Decompensated Heart Failure Syndromes (ATTEND) investigators (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617703061 · Cited by 15
Lee, D. H., Ha, K. H., Kim, H. C., & Kim, D. J. (2018) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2018.27.1.61 · Cited by 13
Cheung, K. K.-T., Jiang, G., Lee, J. S. W., Luk, A. O. Y., Kong, A. P. S., Ozaki, R., Ting, R. Z. W., Ronald, C. W., Chow, F. C. C., Chan, J. C. N., et al. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.12.014 · Cited by 12
Yang, Z., Shen, P., Qu, Y., Xu, L., Li, T., Zhu, Z., Wu, Y., Yu, L., Gao, K., Zhang, X., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101426 · Cited by 12
Wu, M., Chen, Y., Zou, Y., Zhen, Z., Yu, Y., Liu, Y., Yuen, M. M. A., Ho, L., Lam, K. S. L., Tse, H., et al. (2019) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jey217 · Cited by 12
Ferreira, J. P., Rossignol, P., Bakris, G. L., Mehta, C. R., White, W. B., & Zannad, F. M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01382-8 · Cited by 11
“more cachexia, wasting and frailty [7].”
Metadata
- Authors
- Costanzo, P., Cleland, J. G. F., Pellicori, P., Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J., & Atkin, S. L.
- Affiliations
- University of Hull (GB)
- From Hull York Medical School, University of Hull, Kingston upon Hull, United Kingdom; Castle Hill Hospital, Cottingham, United Kingdom; National Heart & Lung Institute, Imperial College, London, United Kingdom; and Federico II University, Naples, Italy.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-05-05
- Volume
- 162
- Issue
- 9
- Pages
- 610-618
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1488210487
- Cited by
- 199
- References
- 49
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 14 · 2023: 16 · 2022: 15 · 2021: 18 · 2020: 20 · 2019: 14 · 2018: 20 · 2017: 16 · 2016: 30 · 2015: 5
- FWCI
- 20.52
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Anglia Ruskin Research Online (Anglia Ruskin University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- Annals of Internal Medicine
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10227)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- obesity paradox, type 2 diabetes, body mass index, overweight, obesity, prognosis, all-cause mortality, cardiovascular morbidity, acute coronary syndrome, heart failure, stroke, underweight
- MeSH terms
- Aged, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Longitudinal Studies, Male, Middle Aged, Obesity, Prognosis, Prospective Studies, Risk Factors, Body Mass Index, Proportional Hazards Models, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.